Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Chinese Patients With Grade II-IV Corticosteroid-refractory Acute Graft Versus Host Disease
NCT06462469Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGVHD), sponsored by Novartis. Started Jul 2024; status: active, not recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT06462469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462469.